<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00697333</url>
  </required_header>
  <id_info>
    <org_study_id>AG NUK/RT 2006-1</org_study_id>
    <nct_id>NCT00697333</nct_id>
  </id_info>
  <brief_title>Radiotherapy Planning Based on Positron Emission Tomography With Fluoro-deoxyglucose For Advanced NSCLC</brief_title>
  <acronym>PET-Plan</acronym>
  <official_title>Optimisation of Radiotherapy-Planning in Patients With Inoperable Locally Advanced Non-Small-Cell Lung Cancer by FDG-PET</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbeitsgemeinschaft Nuklearmedizin und Strahlentherapie der DEGRO und DGN</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arbeitsgemeinschaft Nuklearmedizin und Strahlentherapie der DEGRO und DGN</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Simultaneous radio-chemotherapy in advanced non-small cell lung cancer. The study focusses on
      a randomised comparison of conventional radiotherapy planning with irradiation of macroscopic
      tumor and lymph nodes together with prophylactic target volumes vs. irradiation only of
      FDG-positive lesions.

      Primary endpoint is the local disease control in the chest.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Simultaneous radio-chemotherapy in advanced non-small cell lung cancer. The study focusses on
      a randomised comparison of conventional radiotherapy planning with irradiation of macroscopic
      tumor and lymph nodes together with prophylactic target volumes vs. irradiation only of
      FDG-positive lesions.

      Primary endpoint is the local disease control in the chest
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to local progression</measure>
    <time_frame>actuarial</time_frame>
    <description>Time from randomization to first evidence of local progression or last follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>actuarial</time_frame>
    <description>Time from randomization to death or last follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>normal tissue toxicity</measure>
    <time_frame>actuarial</time_frame>
    <description>Time from randomization to death or last follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>in and out field progression</measure>
    <time_frame>actuarial</time_frame>
    <description>Time from randomization to progression or last follow up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Irradiation of all tumor manifestations detectable by CT and/or positron emission tomography using fluoro-deoxy-glucose including a part of eventual atelectasis and the whole affected lymph node stations by 60 - 74 Gy/2Gy) irradiation of elective lymph node stations up to 50 Gy/2 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irradiation of all tumor manifestations detectable by positron emission tomography using fluoro-deoxy-glucose including the whole affected lymph node stations by 60 - 74 Gy/2Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>restriction of radiotherapy to FDG-PET positive areas only</intervention_name>
    <description>Restriction of target volumes to areas positive in positron emission tomography using fluoro-deoxy-glucose</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically proved NSCLC

          -  UICC-stage I-III, no resection planned

          -  complete staging &lt; 6 wks before treatment including cranial CT

          -  ECOG &lt;3, Karnofsky-Index &gt;60%

          -  age &gt; 18 &lt;

          -  FEV1 &gt; 1,0 l or &gt;35%

          -  RT-planning according to protocol feasible

          -  chemotherapy feasible

          -  written informed consent

        Exclusion Criteria:

          -  neuroendocrine tumors, plain broncho-alveolar-cell ca.

          -  distant metastases, supraclavicular lymph node metastases

          -  malignant pleural effusion

          -  resection of actual tumor performed

          -  inclusion in other study protocol

          -  chemotherapy due to actual tumor before FDG-PET

          -  induction-chemotherapy

          -  acute vena cava superior syndrome

          -  second malignancy other than basalioma

          -  pregnancy, lactation

          -  heart insufficiency NYHA III/IV

          -  pneumoconiosis with active inflammatory changes of mediastinal lymph nodes

          -  acute broncho-pulmonary infection at time of PET-examination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ursula Nestle, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Freiburg, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>U. Nestle, Prof.</last_name>
    <phone>49-761-270</phone>
    <phone_ext>95390</phone_ext>
    <email>ursula.nestle@uniklinik-freiburg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>A. L. Grosu, Prof.</last_name>
    <phone>49-761-270</phone>
    <phone_ext>94610</phone_ext>
    <email>anca.grosu@uniklinik-freiburg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg i.Br.</city>
        <state>Baden-Wuerttemberg</state>
        <zip>D-79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T. Schimek-Jasch, MD</last_name>
      <phone>49-761-270</phone>
      <phone_ext>95201</phone_ext>
      <email>tanja.schimek-jasch@uniklinik-freiburg.de</email>
    </contact>
    <contact_backup>
      <last_name>S. Adebahr, MD</last_name>
      <phone>49-761-270</phone>
      <phone_ext>95371</phone_ext>
      <email>sonja.adebahr@uniklinik-freiburg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Ursula Nestle, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg i. Br.</city>
        <state>Baden-Württemberg</state>
        <zip>D-79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ursula Nestle, Prof.</last_name>
      <phone>49-761-270</phone>
      <phone_ext>95390</phone_ext>
      <email>ursula.nestle@uniklinik-freiburg.de</email>
    </contact>
    <contact_backup>
      <last_name>A.-L. Grosu, Prof.</last_name>
      <phone>49-761-270</phone>
      <phone_ext>94610</phone_ext>
      <email>anca.grosu@uniklinik-freiburg.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Nestle U, Kremp S, Grosu AL. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. Radiother Oncol. 2006 Nov;81(2):209-25. Epub 2006 Oct 24. Review.</citation>
    <PMID>17064802</PMID>
  </reference>
  <reference>
    <citation>Nestle U, Schaefer-Schuler A, Kremp S, Groeschel A, Hellwig D, Rübe C, Kirsch CM. Target volume definition for 18F-FDG PET-positive lymph nodes in radiotherapy of patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007 Apr;34(4):453-62. Epub 2006 Oct 21.</citation>
    <PMID>17058078</PMID>
  </reference>
  <reference>
    <citation>Nestle U, Kremp S, Schaefer-Schuler A, Sebastian-Welsch C, Hellwig D, Rübe C, Kirsch CM. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. J Nucl Med. 2005 Aug;46(8):1342-8.</citation>
    <PMID>16085592</PMID>
  </reference>
  <reference>
    <citation>MacManus M, Nestle U, Rosenzweig KE, Carrio I, Messa C, Belohlavek O, Danna M, Inoue T, Deniaud-Alexandre E, Schipani S, Watanabe N, Dondi M, Jeremic B. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol. 2009 Apr;91(1):85-94. doi: 10.1016/j.radonc.2008.11.008. Epub 2008 Dec 25. Review.</citation>
    <PMID>19100641</PMID>
  </reference>
  <reference>
    <citation>Nestle U, Weber W, Hentschel M, Grosu AL. Biological imaging in radiation therapy: role of positron emission tomography. Phys Med Biol. 2009 Jan 7;54(1):R1-25. doi: 10.1088/0031-9155/54/1/R01. Epub 2008 Dec 5. Review.</citation>
    <PMID>19060363</PMID>
  </reference>
  <reference>
    <citation>Schaefer A, Kremp S, Hellwig D, Rübe C, Kirsch CM, Nestle U. A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data. Eur J Nucl Med Mol Imaging. 2008 Nov;35(11):1989-99. doi: 10.1007/s00259-008-0875-1. Epub 2008 Jul 26.</citation>
    <PMID>18661128</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2008</study_first_submitted>
  <study_first_submitted_qc>June 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2008</study_first_posted>
  <last_update_submitted>July 13, 2016</last_update_submitted>
  <last_update_submitted_qc>July 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Arbeitsgemeinschaft Nuklearmedizin und Strahlentherapie der DEGRO und DGN</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Ursula Nestle</investigator_full_name>
    <investigator_title>Prof. Dr. Ursula Nestle, Universitätsklinikum Freiburg</investigator_title>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>FDG-PET</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>planning</keyword>
  <keyword>target volumes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deoxyglucose</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

